AAN Publications Skip to main content Advertisement . Neurology.org Journals Specialty Sites Collections Podcast CME About Authors . Search for this keyword Advanced Search . Neurology Home The most widely read and highly cited peer-reviewed neurology journal . Subscribe My Alerts Log in Site Logo . Home Latest Articles Current Issue Past Issues Residents & Fellows . Share April 24, 2012; 78 (1 Supplement) April 24,2012 Cortical Thinning in Frontal Lobes Is Relate with Faster Progression of Amyotrophic Lateral Sclerosis (P03.161) Isabella Simone, Domenico Mezzapesa, Eustachio D'Errico, Franca Dicuonzo, Stefano Zoccolella, Rosanna Tortelli, Rosa Cortese, Francesco Federico, Giancarlo Logroscino, Paolo Livrea First published February 8, 2016, . Citation Permissions . Make Comment See Comments . Downloads 0 Article Info & Disclosures Loading Abstract Objective: In this work we measured brain cortical thickness (CT) in a sample of amyotrophic lateral sclerosis (ALS) patients with a wide range of disease duration, in order to explore whereas some regions may be associated with faster or slower progression. Background ALS is a neurodegenerative disease of motor neurons which is heterogeneous in terms of clinical phenotypes, disability progression and prognosis. Few studies investigated the brain CT in correlation with clinical features, and disease progression particularly, in ASL patients. Design/Methods: Twenty-three patients with probable or definite ALS were studied (half of the patients had a disease duration higher than 24 months). Slow or fast progression was defined according to an index which included duration and severity of the disease. CT was measured from 3D-MRI using FreeSurfer, a set of automated tools for reconstruction of the brain's cortical surface. Statistics was performed both at a whole brain vertex-wise and at a region-wise level. Results: ALS patients compared to controls revealed cortical thinning in right caudal middle frontal gyrus (MFG), right superior frontal gyrus (SFG) and left fusiform gyrus (FG). Patients with fast progression showed thinning in bilateral MFG, in right SFG and in left FG compared to controls. No areas of cortical thinning were found in patients with slow progression compared to control. Conclusions: Our study demonstrated that in term of brain CT the hallmark of ALS is located in the frontal lobes, without a direct involvement of the primary motor areas. The cortical thinning regards mostly the bilateral MFG of patients with faster evolution, as if it characterizes different phenotypes in term of disease progression. Supported by: Research grant Progetto Ordinario Regione Puglia 2007-652596. Disclosure: Dr. Simone has received personal compensation for activities with Sanofi-Aventis and Biogen Idec. Dr. Mezzapesa has nothing to disclose. Dr. D'Errico has nothing to disclose. Dr. Dicuonzo has nothing to disclose. Dr. Zoccolella has nothing to disclose. Dr. Tortelli has nothing to disclose. Dr. Cortese has nothing to disclose. Dr. Federico has nothing to disclose. Dr. Logroscino has received personal compensation for activities with Novartis, Glaxo and Boerhinger. Dr. Livrea has received personal compensation for activities with Sanofi-Aventis, Pfizer, Novartis, and Lundbeck as a speaker.
Cortical Thinning in Frontal Lobes Is Relate with Faster Progression of Amyotrophic Lateral Sclerosis
SIMONE, Isabella Laura;DICUONZO, Franca;Federico, F;LOGROSCINO, Giancarlo;Livrea P.
2012-01-01
Abstract
AAN Publications Skip to main content Advertisement . Neurology.org Journals Specialty Sites Collections Podcast CME About Authors . Search for this keyword Advanced Search . Neurology Home The most widely read and highly cited peer-reviewed neurology journal . Subscribe My Alerts Log in Site Logo . Home Latest Articles Current Issue Past Issues Residents & Fellows . Share April 24, 2012; 78 (1 Supplement) April 24,2012 Cortical Thinning in Frontal Lobes Is Relate with Faster Progression of Amyotrophic Lateral Sclerosis (P03.161) Isabella Simone, Domenico Mezzapesa, Eustachio D'Errico, Franca Dicuonzo, Stefano Zoccolella, Rosanna Tortelli, Rosa Cortese, Francesco Federico, Giancarlo Logroscino, Paolo Livrea First published February 8, 2016, . Citation Permissions . Make Comment See Comments . Downloads 0 Article Info & Disclosures Loading Abstract Objective: In this work we measured brain cortical thickness (CT) in a sample of amyotrophic lateral sclerosis (ALS) patients with a wide range of disease duration, in order to explore whereas some regions may be associated with faster or slower progression. Background ALS is a neurodegenerative disease of motor neurons which is heterogeneous in terms of clinical phenotypes, disability progression and prognosis. Few studies investigated the brain CT in correlation with clinical features, and disease progression particularly, in ASL patients. Design/Methods: Twenty-three patients with probable or definite ALS were studied (half of the patients had a disease duration higher than 24 months). Slow or fast progression was defined according to an index which included duration and severity of the disease. CT was measured from 3D-MRI using FreeSurfer, a set of automated tools for reconstruction of the brain's cortical surface. Statistics was performed both at a whole brain vertex-wise and at a region-wise level. Results: ALS patients compared to controls revealed cortical thinning in right caudal middle frontal gyrus (MFG), right superior frontal gyrus (SFG) and left fusiform gyrus (FG). Patients with fast progression showed thinning in bilateral MFG, in right SFG and in left FG compared to controls. No areas of cortical thinning were found in patients with slow progression compared to control. Conclusions: Our study demonstrated that in term of brain CT the hallmark of ALS is located in the frontal lobes, without a direct involvement of the primary motor areas. The cortical thinning regards mostly the bilateral MFG of patients with faster evolution, as if it characterizes different phenotypes in term of disease progression. Supported by: Research grant Progetto Ordinario Regione Puglia 2007-652596. Disclosure: Dr. Simone has received personal compensation for activities with Sanofi-Aventis and Biogen Idec. Dr. Mezzapesa has nothing to disclose. Dr. D'Errico has nothing to disclose. Dr. Dicuonzo has nothing to disclose. Dr. Zoccolella has nothing to disclose. Dr. Tortelli has nothing to disclose. Dr. Cortese has nothing to disclose. Dr. Federico has nothing to disclose. Dr. Logroscino has received personal compensation for activities with Novartis, Glaxo and Boerhinger. Dr. Livrea has received personal compensation for activities with Sanofi-Aventis, Pfizer, Novartis, and Lundbeck as a speaker.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
